Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse

Yang, F; Brady, SW; Tang, C; Sun, HY; Du, LJ; Barz, MJ; Ma, XT; Chen, Y; Fang, HS; Li, XM; Kolekar, P; Pathak, O; Cai, JY; Ding, LX; Wang, TY; von Stackelberg, A; Shen, SH; Eckert, C; Klco, JM; Chen, HZ; Duan, CW; Liu, Y; Li, H; Li, BS; Kirschner-Schwabe, R; Zhang, JH; Zhou, BBS

Cai, JY; Zhou, BBS (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr,Key Lab Pediat Hematol, Minist Hlth,Pediat Translat Med Inst,Dept Hematol, Shanghai, Peoples R China.; Zhang, JH (corresponding author), St Jude Childrens Res Hosp, Dept Computat Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.; Kirschner-Schwabe, R (corresponding author), Charite Univ Med Berlin, Dept Pediat Oncol Hematol, Berlin, Germany.; Kirschner-Schwabe, R (corresponding author), German

NATURE CANCER, 2021; 2 (8): 819

Abstract

Chemotherapy is a standard treatment for pediatric acute lymphoblastic leukemia (ALL), which sometimes relapses with chemoresistant features. However,......

Full Text Link